Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01773122 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris
A Phase 1 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT01773122: Completed Phase 1 study, sponsored by Allergan.
NCT01773122 is a Phase 1 study that has completed, run by Allergan. The registered enrollment target is 77 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01773122, a Phase 1 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of dapsone in subjects with acne vulgaris following 28 days of dosing.
Primary Outcome
Cmax is the maximum plasma level following multiple doses of dapsone. Plasma is the liquid component of the blood in which the blood cells are suspended.
Interventions
- DRUG Dapsone Formulation A
- DRUG Dapsone Formulation B
- DRUG Dapsone Formulation C
- DRUG Dapsone 5% Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2013-01-21 |
| Est. Completion | 2013-05-05 |
| Phase | Phase 1 |
What the finished NCT01773122 record still lists
NCT01773122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% higher).
The record links to 0 conditions, and to 4 interventions - of which Dapsone Formulation A is the first listed.
NCT01773122 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01773122 about?
NCT01773122 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris". This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of dapsone in subjects with acne vulgaris following 28 days of dosing.
What is the current status of trial NCT01773122?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2013-01-21. Estimated completion is 2013-05-05.
What interventions are being tested in trial NCT01773122?
The interventions under investigation include: Dapsone Formulation A (DRUG), Dapsone Formulation B (DRUG), Dapsone Formulation C (DRUG), Dapsone 5% Gel (DRUG).
Who is sponsoring clinical trial NCT01773122?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01773122's enrollment target sits among peer trials
77 703rd of 2000 higher than 1,296 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI